The cationic tetradecapeptide mastoparan as a privileged structure for drug discovery: Enhanced antimicrobial properties of mitoparan analogues modified at position-14

•The mitochondriotoxic tetradecapeptide mitoparan (MitP) is a convenient molecular template for the design and synthesis of antimicrobial peptides.•Rational modification to the carboxyl-terminal of MitP engineered analogues that lack several unwanted influences upon eukaryotic cells.•As exemplified...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Peptides (New York, N.Y. : 1980) N.Y. : 1980), 2018-03, Vol.101, p.95-105
Hauptverfasser: Howl, John, Howl, Lewis, Jones, Sarah
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•The mitochondriotoxic tetradecapeptide mitoparan (MitP) is a convenient molecular template for the design and synthesis of antimicrobial peptides.•Rational modification to the carboxyl-terminal of MitP engineered analogues that lack several unwanted influences upon eukaryotic cells.•As exemplified by [Ser14]MitP, these studies identified novel peptides active against both prokaryotic, and eukaryotic human pathogens. Mastoparan (MP) peptides, distributed in insect venoms, induce a local inflammatory response post envenomation. Most endogenous MPs share common structural elements within a tetradecapeptide sequence that adopts an amphipathic helix whilst traversing biological membranes and when bound to an intracellular protein target. Rational modifications to increase cationic charge density and amphipathic helicity engineered mitoparan (MitP), a mitochondriotoxic bioportide and potent secretagogue. Following intracellular translocation, MitP is accreted by mitochondria thus indicating additional utility as an antimicrobial agent. Hence, the objectives of this study were to compare the antimicrobial activities of a structurally diverse set of cationic cell penetrating peptides, including both MP and MitP sequences, and to chemically engineer analogues of MitP for potential therapeutic applications. Herein, we confirm that, like MP, MitP is a privileged structure for the development of antimicrobial peptides active against both prokaryotic and eukaryotic pathogens. Collectively, MitP and target-selective chimeric analogues are broad spectrum antibiotics, with the Gram-negative A. baumannii demonstrating particular susceptibility. Modifications of MitP by amino acid substitution at position-14 produced peptides, Δ14MitP analogues, with unique pharmacodynamic properties. One example, [Ser14]MitP, lacks both cytotoxicity against human cell lines and mast cell secretory activity yet retains selective activity against the encapsulated yeast C. neoformans.
ISSN:0196-9781
1873-5169
DOI:10.1016/j.peptides.2018.01.007